MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Zhao, Na ^a   Wang, Ruizhi ^a   Zhou, Liangji ^a   Zhu, Ying ^a   Gong, Jiao ^a   Zhuang, Shi Mei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MiR 26b; NF B signaling; Noncoding RNA; TAB3; TAK1

Indexed keywords

DOXORUBICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 26B; PROTEIN; SYNAPTOTAGMIN I; TAB3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING SITE; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUCIFERASE ASSAY; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MAP KINASE KINASE KINASES; MICRORNAS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84896718544     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-35     Document Type: Article

References (34)

1. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
2. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723. 10.1038/ni.2060, 21772280.
3. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012, 33:522-530. 10.1016/j.tips.2012.06.007, 22795313.
4. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012, 246:311-326. 10.1111/j.1600-065X.2012.01101.x, 3311051, 22435563.
5. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J 2011, 30:57-67. 10.1038/emboj.2010.296, 3020116, 21113131.
6. Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, Fang L, Yan X, He M, Li J, Li M. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest 2012, 122:33-47. 10.1172/JCI58849, 3248293, 22156201.
7. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 2012, 122:3563-3578. 10.1172/JCI62339, 3589141, 23006329.
8. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113:6669-6680. 10.1182/blood-2009-01-198408, 2710922, 19401561.
9. Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, Liang L, Li J, He X. Genome-wide screening reveals that miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology 2013, 58:654-666. 10.1002/hep.26378, 23487264.
10. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008, 27:5643-5647. 10.1038/onc.2008.171, 2811234, 18504431.
11. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009, 276:6689-6700. 10.1111/j.1742-4658.2009.07383.x, 19843160.
12. Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM, Heo DS, Kim CW. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 2011, 17:4761-4771. 10.1158/1078-0432.CCR-11-0494, 21610143.
13. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002, 37:63-71. 10.1016/S0168-8278(02)00064-8, 12076863.
14. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009, 69:1135-1142.
15. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 2012, 40:4615-4625. 10.1093/nar/gkr1278, 3378857, 22210897.
16. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447. 10.1056/NEJMoa0901282, 2786938, 19812400.
17. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011, 32:2-9. 10.1093/carcin/bgq209, 20952513.
18. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011, 71:225-233. 10.1158/0008-5472.CAN-10-1850, 21199804.
19. Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol 2013, 133:1286-1293. 10.1038/jid.2012.400, 3898712, 23190898.
20. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
21. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013, 65:157-170. 10.1111/j.2042-7158.2012.01567.x, 23278683.
22. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005, 224:53-65. 10.1016/j.canlet.2004.10.051, 15911101.
23. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010, 2:a000109. 2869521, 20516126.
24. Boland MP. Daunorubicin Activates NFkappa B and Induces kappa B-dependent Gene Expression in HL-60 Promyelocytic and Jurkat T Lymphoma Cells. J Biol Chem 1997, 272:12952-12960. 10.1074/jbc.272.20.12952, 9148901.
25. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, Peyron JF. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001, 61:7785-7791.
26. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004, 13:853-865. 10.1016/S1097-2765(04)00131-5, 15053878.
27. Ho WC, Dickson KM, Barker PA. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 2005, 65:4273-4281. 10.1158/0008-5472.CAN-04-3494, 15899819.
28. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805, 2010:167-180.
29. Wen J, Hu Y, Luo KJ, Yang H, Zhang SS, Fu JH. Positive transforming growth factor-beta activated kinase-1 expression has an unfavorable impact on survival in T3N1-3 M0 esophageal squamous cell carcinomas. Ann Thorac Surg 2013, 95:285-290. 10.1016/j.athoracsur.2012.09.050, 23272845.
30. Wei C, Lai Y-Q, Li X-X, Ye J-X. TGF-β-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pacific J Cancer Prev 2013, 14:315-320.
31. Jin G, Klika A, Callahan M, Faga B, Danzig J, Jiang Z, Li X, Stark GR, Harrington J, Sherf B. Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci USA 2004, 101:2028-2033. 10.1073/pnas.0307314101, 357046, 14766965.
32. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017. 10.1016/j.cell.2009.04.021, 2722880, 19524505.
33. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013, 58:158-170. 10.1002/hep.26305, 23389848.
34. Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, He M, Chen GQ, He JR, Zhao Q. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett 2011, 585:1363-1367. 10.1016/j.febslet.2011.04.018, 21510944.